Nasus Pharma (NSRX) Enterprise Value (2024 - 2025)
Nasus Pharma's (NSRX) quarterly Enterprise Value came in at -$4.3 million in Q4 2025, down 1295.5% YoY from $363028.5 in Q4 2024, and down 1770.69% on a QoQ basis from -$232000.0 in Q2 2025.
Nasus Pharma (NSRX) Enterprise Value (2024 - 2025) Analysis & Trends
Nasus Pharma (NSRX) has 2 years of Enterprise Value data on file, last reported at -$4.3 million in Q4 2025.
- Quarterly Enterprise Value fell 1295.5% year-over-year to -$4.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$4.3 million (down 1295.5% YoY) and the FY2025 annual result came in at -$4.3 million, down 373.8% from the prior year.
- Enterprise Value fell to -$4.3 million in Q4 2025, from -$232000.0 in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$232000.0 in Q2 2025 to a low of -$4.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.87 Bn | 633.12 Bn | 17.26 Bn | -20.76 Bn |
| 2 | AbbVie | 470.41 Bn | 463.84 Bn | 12.70 Bn | -6.52 Bn |
| 3 | Merck | 376.13 Bn | 368.99 Bn | 12.21 Bn | -7.09 Bn |
| 4 | Novartis Ag | 303.87 Bn | 296.18 Bn | 11.24 Bn | -7.69 Bn |
| 5 | Astrazeneca | 257.75 Bn | 252.85 Bn | 12.86 Bn | -4.90 Bn |
| 6 | Amgen | 236.40 Bn | 222.41 Bn | 7.24 Bn | -13.99 Bn |
| 7 | Gilead Sciences | 182.11 Bn | 178.93 Bn | 6.22 Bn | -3.26 Bn |
| 8 | Pfizer | 159.54 Bn | 147.84 Bn | 10.94 Bn | -11.40 Bn |
| 9 | Gsk | 106.30 Bn | 102.13 Bn | 8.24 Bn | -4.80 Bn |
| 10 | Nasus Pharma | 31.88 Mn | 31.88 Mn | - | -4.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.34 Mn |
| Jun 30, 2025 | -232,000.00 |
| Dec 31, 2024 | -311,000.00 |